Livforsakringsbolaget Skandia Omsesidigt Buys 1,200 Shares of Cencora, Inc. (NYSE:COR)

Livforsakringsbolaget Skandia Omsesidigt raised its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 4.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 28,575 shares of the company's stock after acquiring an additional 1,200 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt's holdings in Cencora were worth $6,420,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Concord Wealth Partners bought a new position in Cencora during the 3rd quarter worth approximately $30,000. Householder Group Estate & Retirement Specialist LLC increased its position in shares of Cencora by 85.2% in the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock valued at $33,000 after buying an additional 69 shares in the last quarter. Ashton Thomas Securities LLC bought a new stake in shares of Cencora in the 3rd quarter valued at $41,000. Modus Advisors LLC acquired a new stake in Cencora during the 4th quarter worth $54,000. Finally, Carolina Wealth Advisors LLC lifted its holdings in Cencora by 366.7% during the third quarter. Carolina Wealth Advisors LLC now owns 266 shares of the company's stock worth $60,000 after acquiring an additional 209 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.

Cencora Stock Up 0.2 %

Shares of NYSE:COR traded up $0.48 during trading on Tuesday, hitting $246.86. 1,076,644 shares of the company were exchanged, compared to its average volume of 1,476,687. The company has a current ratio of 0.92, a quick ratio of 0.53 and a debt-to-equity ratio of 16.40. The firm has a fifty day moving average price of $238.86 and a two-hundred day moving average price of $237.03. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $262.26. The stock has a market cap of $47.71 billion, a price-to-earnings ratio of 35.11, a P/E/G ratio of 1.49 and a beta of 0.49.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, research analysts anticipate that Cencora, Inc. will post 15.36 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Investors of record on Friday, February 14th will be paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date is Friday, February 14th. Cencora's dividend payout ratio (DPR) is presently 31.29%.

Analyst Ratings Changes

COR has been the topic of a number of research analyst reports. Barclays raised their price target on Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a research report on Thursday, November 7th. Robert W. Baird lifted their price target on shares of Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a research note on Thursday, November 7th. Evercore ISI upped their price target on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. Wells Fargo & Company raised their price objective on shares of Cencora from $237.00 to $251.00 and gave the stock an "equal weight" rating in a report on Wednesday, January 29th. Finally, UBS Group upped their target price on shares of Cencora from $275.00 to $285.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $277.90.

Insider Buying and Selling at Cencora

In related news, EVP Silvana Battaglia sold 1,678 shares of the business's stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the sale, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. The trade was a 7.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Chairman Steven H. Collis sold 21,509 shares of the company's stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total value of $5,208,619.44. Following the completion of the transaction, the chairman now directly owns 306,752 shares in the company, valued at approximately $74,283,064.32. This represents a 6.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 73,187 shares of company stock worth $17,790,912 over the last ninety days. Insiders own 10.80% of the company's stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.